Obulytix Strengthens Senior Leadership with Key Executive and Board Appointments
Ghent, Belgium – November 27th, 2025 – Obulytix, the biotechnology company pioneering Precision Lysin Therapeutics (PLTs)—a novel class of targeted biologics designed as next-generation antibiotics—today announces the appointment of Guy Hermans as Chief Scientific Officer (CSO) and Lisa Patel as Chair of the Board of Directors.
Guy Hermans joins Obulytix with over 20 years of expertise in biologics discovery, early development, and discovery technology innovation. His previous leadership roles include CEO at Sapreme Technologies, CSO at Isogenica, and Research Fellow at Ablynx, where he initiated and advanced numerous internal drug discovery programs through early development.
Lisa Patel brings more than 25 years of experience across biotech and pharma, spanning discovery through development, alongside over a decade as a life sciences investor. She has held senior roles at GlaxoSmithKline plc and IP Group plc and served as a non-executive director for multiple biopharmaceutical companies. Lisa currently serves as Co-Founder and CEO of Istesso Ltd.
“I’m delighted to join Obulytix at such an exciting stage,” said Lisa Patel. “The company’s pioneering approach has the potential to deliver transformative solutions for antimicrobial resistance, and I look forward to supporting Obulytix’s continued growth and progress.”
Kristof Van Emelen, CEO of Obulytix, commented: “We are thrilled to welcome Lisa and Guy to Obulytix. Their proven track record in developing innovative therapies and driving strategic growth will be invaluable as we scale the company and accelerate our mission.”
About Obulytix
Obulytix (www.obulytix.com) is a Belgium-based preclinical-stage biotech company developing Precision Lysin Therapeutics (PLTs)—a novel class of targeted biologics that rapidly and selectively eliminate drug-resistant bacteria without promoting antimicrobial resistance. Inspired by antibody-drug conjugates in oncology, PLTs are engineered proteins that disrupt bacterial cell walls via a non-metabolic mechanism, significantly reducing the likelihood of resistance development.
The company’s strategic focus is on life-threatening, multidrug-resistant Gram-negative bacterial infections, an urgent unmet medical need in critically ill patients. Leveraging a proprietary platform that integrates synthetic biology, high-throughput screening under physiological conditions, and AI-enabled prediction tools, Obulytix has successfully engineered PLTs demonstrating potent in vivo activity.
Antimicrobial Resistance (AMR) remains a major global health threat. In 2021 alone, AMR was associated with 4.7 million deaths worldwide, with one in five occurring in children under five years old—underscoring the urgent need for new, effective antimicrobial therapeutics.
Contact
Corporate: Kristof Van Emelen, CEO info@obulytix.com
Media relations: Maria Fonseca, Portfolio Lead maria.fonseca@obulytix.com
Phone: +32(0)9 229 06 92